A liposome composition of docetaxel and preparation method thereof
By adding mannose and natural phospholipids to docetaxel liposomes, and preparing by film evaporation-freeze-drying method, the poor water solubility and toxic side effects of docetaxel were solved, and the stability of liposomes was improved and drug selectivity, achieving better anti-tumor effects and safety.
Patent Information
- Application Number
- CN202111066827.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2021-09-13
- Publication Date
- 2024-11-29
- Estimated Expiration
- 2041-09-13
AI Technical Summary
Docetaxel has poor water solubility and non-selective toxic side effects, poor current liposome stability and high drug leakage rate, resulting in adverse reactions and poor treatment effects of injections.
Liposomes were prepared by thin-film evaporation-freeze-drying method using docetaxel, natural soy lecithin, antioxidants, lyophilized protective agents and mannose in carriers to improve drug stability and targeting.
It improves the stability of liposomes and drug selectivity, reduces adverse reactions, enhances anti-tumor effects, simplifies production processes and reduces costs.
Smart Images

Figure CN115804755B_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of medical technology, and specifically relates to a docetaxel liposome composition and a preparation method. Background Art
[0002] Docetaxel is a new generation of taxane anticancer drugs obtained by semi-synthesis of natural compounds extracted from yew needles. Docetaxel can both enhance tubulin polymerization and inhibit microtubule depolymerization, leading to the formation of stable non-functional microtubule bundles in tumor cells, thereby destroying the mitosis of tumor cells. Docetaxel is currently the first-line drug for the treatment of tumors such as colon cancer, breast cancer, non-small cell lung cancer, ovarian cancer, and melanoma. Docetaxel has poor water solubility and is a fat-soluble compound. Currently, the only dosage forms available in China are injections, which are Dopafil and Taxotere. However, the injection contains a large amount of ethanol and Tween as cosolvents. It is easy to cause adverse reactions such as hemolysis and allergies, and antiallergic drugs need to be given in advance to slow down allergic reactions. In addition, docetaxel has poor selectivity for multiple tissues. While killing tumor cells, the drug will also kill normal cells, causing toxic side effects such as neutropenia, peripheral neurotoxicity, and cardiovascular reactions in tissues and organs, making the patient's compliance poor.
[0003] In 1965, British scientist Bangham A first proposed the concept of liposomes. Due to the hydration of liposomes, they form a lipid membrane with a closed concentric spherical structure, encapsulating the liquid solvent. The basic composition of a liposome is phospholipids - the molecules contain a hydrophilic "head" composed of phosphate groups, connected to a non-polar hydrophobic "tail" composed of two hydrocarbon chains. The amphiphilic structure of phospholipids allows them to be arranged in an ordered structure - so that the hydrophobic tail cannot come into contact with water.
[0004] Hydrophilic drugs are encapsulated in the water phase, and lipophilic drugs are encapsulated in the phospholipid bilayer. Due to the targeting, lymphatic orientation, sustained release, reduced drug toxicity, and improved stability of liposomes, it is the most marketed dosage form to date. However, at the same time, the liposome itself has poor stability, and is prone to particle size enlargement and drug leakage during storage. The film-forming material is easily oxidized, which is an urgent problem that needs to be solved.
[0005] Patent CN202010904850 discloses a docetaxel liposome and a preparation method thereof, which is prepared by thin film evaporation-freeze drying method using saturated phospholipids and ginsenosides as film-forming materials, vitamin E as an antioxidant, and trehalose as a lyophilization excipient. This liposome can be used as a carrier of the anticancer drug docetaxel. Patent CN103462906A discloses a docetaxel nanoparticle for injection and a preparation method thereof, which is prepared by freeze drying. The above solutions all use a single sucrose or trehalose as a lyophilization protectant, which increases the drug leakage rate and does not have a synergistic drug to enhance the anti-tumor effect of the drug.
[0006] Mannose, the only carbohydrate nutrient currently used in clinical practice, is widely distributed in body fluids and tissues, especially in nerves, skin, testicles, retina, liver and intestines. It is directly used to synthesize glycoproteins and participate in immune regulation. Recent studies have found that mannose-6-phosphate can inhibit three enzymes involved in glucose metabolism: hexokinase, phosphoglucose isomerase (PGI) and glucose-6-phosphate dehydrogenase, thereby affecting the tricarboxylic acid cycle, pentose phosphate pathway and polysaccharide synthesis, so mannose can inhibit tumor growth without affecting the uptake of glucose. At the same time, further studies have found that mannose can increase the response of tumor cells to chemotherapy drugs. Patent CN105585598A introduces a method for preparing mannose derivative cationic liposome nanoparticles, which uses mannose derivatives with good cationic solubility and combines with nucleic acid drugs through hydrophobic bonds to enable cells to engulf drugs to achieve therapeutic effects, but there is no drug targeting. Patent CN102670484A introduces a mannose-modified solid lipid nanoparticle composite gel and its preparation method, but it uses the principle that mannose can increase solubility, but does not explain the principle that it can increase drug targeting. It can be seen that the above records use mannose to use it in the corresponding preparations by utilizing its good solubility characteristics, but there is no clear report on its use in the preparation of targeted liposomes. Summary of the invention
[0007] The present invention aims to provide a liposome composition of docetaxel and a preparation method thereof.
[0008] To achieve the above purpose, the present invention adopts the following technical solution:
[0009] A docetaxel liposome composition, comprising: 1) docetaxel or a derivative thereof; 2) a lipid membrane material; and 3) other excipients for preparing liposome drugs; in terms of mass percentage, the composition comprises: 0.01%-10% docetaxel or a derivative thereof, 20%-50% lipid membrane material, and the remainder is other excipients for preparing liposome drugs; wherein the other excipients for preparing liposome drugs are antioxidants, lyophilization protective agents, and carriers, the carriers contain mannose, and the amount of mannose added is % of the mass of the carriers.
[0010] The other auxiliary materials used for preparing liposome drugs are calculated by weight percentage, including 20%-50% freeze-drying protective agent and 15%-50% carrier, and the balance is antioxidant.
[0011] The lipid membrane material is one or more of natural soybean lecithin, egg yolk lecithin, sphingomyelin, cholesterol, hydrogenated soybean lecithin, dioleoylphosphatidylcholine, dimyristoylphosphatidylcholine, 1-palmitoyl-2-oleoyl lecithin, distearoylphosphatidylglycerol, dipalmitoylphosphatidylglycerol, dimyristoylphosphatidylglycerol, and phosphatidylethanolamine, preferably hydrogenated soybean lecithin.
[0012] The antioxidant component is one or more of α-tocopherol, vitamin E, threonine, lysine, and vitamin C; vitamin E is preferred.
[0013] The freeze-drying protective agent is one or more of glucose, mannitol, trehalose, lactose, sucrose, and dextran; preferably trehalose.
[0014] The carrier is mannose or a mixture containing mannose. The mixture containing mannose is a mixture of mannose and one or more of the following substances, wherein the following substances are selected from sodium chloride, glucose, lactose, sucrose, and trehalose; preferably, it is a mixture of mannose and trehalose.
[0015] The mannose is chitosan obtained by sugar metabolism of mannose, aminomannose, chitosan, and octadecylamine, preferably mannose.
[0016] A method for preparing a docetaxel liposome composition:
[0017] (1) Film formation: docetaxel or its derivative, lipid film material and antioxidant are mixed with an organic solvent according to the above proportions, a carrier is added after mixing, and the mixture is further mixed. After mixing, the organic solvent is removed by heating at 20° C. to 80° C. under reduced pressure to obtain a dry film;
[0018] (2) Hydration: Add a hydration medium containing a lyophilization protective agent to the obtained dry film, and stir in a constant temperature water bath at 20° C. to 80° C. to obtain a liposome suspension;
[0019] (3) Granulation: The liposome suspension is granulated by microfluidization, high-pressure homogenization, ultrasound or extrusion to obtain a liposome intermediate; the intermediate is filtered, sterilized and freeze-dried to obtain the liposome.
[0020] The antioxidant, lyophilization protectant and carrier are all added in the above proportions; wherein the lyophilization protectant is added in step (2).
[0021] The organic solvent is one or more of anhydrous ethanol, dichloromethane and chloroform.
[0022] The hydration medium is one or more of purified water, physiological saline, pH 3-8 buffered salt solution, threonine solution, and glycine solution.
[0023] Advantages of the present invention:
[0024] The composition of the invention has low cost, high quality, stable and uniform properties, simple process, and stable preparation after freeze-drying, which is conducive to large-scale industrial production, reduces production costs, avoids fluctuations in liposome particle size and encapsulation rate, and improves the safety of clinical medication.
[0025] The introduction of mannose into the composition of the present invention can, on the one hand, reduce the problem of easy leakage of fat-soluble drugs in liposomes; on the other hand, mannose can cooperate with drugs to play an anti-tumor synergistic role. In addition, there are a large number of mannose receptors on the surface of macrophages and dendritic cells in the body, and the addition of mannose is beneficial to regulating immune balance. BRIEF DESCRIPTION OF THE DRAWINGS
[0026] Figure 1 This is a diagram of a liposome product provided by an embodiment of the present invention. DETAILED DESCRIPTION
[0027] The specific implementation modes of the present invention are further described below in conjunction with examples. It should be noted that the specific implementation modes described here are only for illustrating and explaining the present invention, and are not limited to the present invention.
[0028] Embodiment 1:
[0029] First, 20 mg of docetaxel, 40 mg of cholesterol, 369.2 mg of soy lecithin, 30.8 mg of phosphatidylethanolamine, and 0.1 mg of vitamin E in a round-bottom flask were placed, and an appropriate amount of ethanol was added to the mixture to completely dissolve it into a clear solution, and 0.8 g of mannose was added thereto and evenly dispersed, and the organic solvent was removed by heating at 60° C. under reduced pressure to obtain a dry powder;
[0030] 0.6 g of sucrose was added to a certain amount of purified water, and then added to the dry powder obtained above, and magnetically stirred at a high speed of 2500 r / min in a 40°C water bath for 30 minutes to obtain liposomes with uneven particle size; then the particle size was reduced to 70-120 nm using an ultrasonic cell crusher), and the intermediate was sterilized by filtration using a 0.22 μm microporous filter membrane at room temperature and packaged in 40 mL vials; the drug-containing liposome solution was vacuum freeze-dried to remove moisture to obtain a white lyophilized powder.
[0031] Embodiment 2:
[0032] First, 20 mg of docetaxel, 40 mg of cholesterol, 240 mg of soy lecithin, 160 mg of egg yolk lecithin (PL-100M), and 0.1 mg of vitamin E were placed in a round-bottom flask, and an appropriate amount of ethanol was added to the mixture to completely dissolve it into a clear solution, 1.6 g of mannose was added thereto and evenly dispersed, and the organic solvent was removed by heating at 60° C. under reduced pressure to obtain a dry powder;
[0033] 0.6 g of trehalose was added to a certain amount of purified water, and then added to the dry powder obtained above, and magnetically stirred at a high speed of 3000 r / min in a 40°C water bath for 30 min to obtain liposomes with uneven particle size; the particle size was reduced to 70-120 nm using an ultrasonic cell crusher, and the intermediate was sterilized by filtering with a 0.22 μm microporous filter membrane at room temperature and dispensed into 40 mL vials; the drug-containing liposome solution was vacuum freeze-dried to remove moisture to obtain a white freeze-dried powder.
[0034] Embodiment 3:
[0035] First, 20 mg of docetaxel, 40 mg of cholesterol, 240 mg of soy lecithin, 160 mg of egg yolk lecithin (PL-100M), and 0.1 mg of vitamin E in a round-bottom flask were placed, and an appropriate amount of ethanol was added to the mixture to completely dissolve it into a clear solution, 0.8 g of glucose and 0.8 g of mannitol were added thereto and evenly dispersed, and the organic solvent was removed by heating at 60° C. under reduced pressure to obtain a dry powder;
[0036] 0.6 g of mannose was added to a certain amount of purified water, and then added to the dried powder after rotary evaporation. The mixture was magnetically stirred at a high speed of 2500 r / min in a 40°C water bath for 30 min to obtain liposomes with uneven particle size. The particle size was reduced to 70-120 nm using an ultrasonic cell crusher. The intermediate was sterilized by filtering with a 0.22 μm microporous filter membrane at room temperature and dispensed into 40 mL vials. The drug-containing liposome solution was freeze-dried in vacuum to remove moisture to obtain a white freeze-dried powder.
[0037] Embodiment 4:
[0038] First, 20 mg of docetaxel, 40 mg of cholesterol, 400 mg of soy lecithin, and 0.1 mg of vitamin E in a prescribed amount are placed in a round-bottom flask, and an appropriate amount of ethanol is added to the mixture to completely dissolve it into a clear solution, 1.6 g of mannose is added thereto and evenly dispersed, and the organic solvent is removed by heating at 40° C. and reducing pressure to obtain a dry powder;
[0039] 1.6 g of sucrose was added to a certain amount of purified water, and then added to the dried powder after rotary evaporation. The mixture was magnetically stirred at a high speed of 2500 r / min in a 40°C water bath for 30 min to obtain liposomes with uneven particle size. The particle size was reduced to 70-120 nm using an ultrasonic cell crusher. The intermediate was sterilized by filtering with a 0.22 μm microporous filter membrane at room temperature and dispensed into 40 mL vials. The drug-containing liposome solution was freeze-dried in vacuum to remove moisture to obtain a white freeze-dried powder.
[0040] Embodiment 5:
[0041] First, 20 mg of docetaxel, 40 mg of cholesterol, 400 mg of soy lecithin, and 0.1 mg of vitamin E in a prescribed amount are placed in a round-bottom flask, and an appropriate amount of ethanol is added to the mixture to completely dissolve it into a clear solution, and 0.8 g of trehalose and 0.8 g of mannose are added thereto and evenly dispersed, and the organic solvent is removed by heating at 60° C. under reduced pressure to obtain a dry powder;
[0042] 0.6 g of lactose was added to a certain amount of purified water, and then added to the dried powder after rotary evaporation, and magnetically stirred at a high speed of 2400 r / min in a 40°C water bath for 30 minutes to obtain liposomes with uneven particle size; the particle size was reduced to 70-120 nm using an ultrasonic cell crusher, and the intermediate was sterilized by filtering with a 0.22 μm microporous filter membrane at room temperature and dispensed into 40 mL vials; the drug-containing liposome solution was vacuum freeze-dried to remove moisture to obtain a white freeze-dried powder.
[0043] Embodiment 6:
[0044] First, 400 mg of docetaxel, 800 mg of cholesterol, 8 g of soy lecithin, and 2 mg of vitamin E (20 times the amount of the prescription) were placed in a round-bottom flask, and an appropriate amount of ethanol was added to the mixture to completely dissolve it into a clear solution, 32 g of mannose was added thereto and evenly dispersed, and the organic solvent was removed by heating at 40° C. under reduced pressure to obtain a dry powder;
[0045] Add 32g of trehalose to a certain amount of purified water, and add it to the dry powder, stir it magnetically in a 40℃ water bath at a speed of 3000r / min for 30min until it is completely hydrated to obtain liposomes with uneven particle size; use a microfluidizer to reduce the particle size to 70-120nm, filter the intermediate with a 0.22μm microporous filter at room temperature for sterilization, and dispense it into 40mL vials; vacuum freeze-dry the drug-containing liposome solution to remove moisture to obtain white lyophilized powder. Encapsulation efficiency determination method: microcolumn centrifugation method.
[0046] Particle size and dispersion coefficient determination method: The intermediate obtained by preparing liposomes in the above-mentioned embodiments and comparative examples was diluted a certain multiple and measured using a ZetaSizer nano Malvern particle size analyzer.
[0047] In vitro cell experiment: The model was B16 melanoma cells. The drug was administered 24 days after plating. After incubation for 48 hours, CCK8 was added to measure the absorbance at a wavelength of 450.
[0048] In vivo efficacy test: C57BL / 6 mice were subcutaneously inoculated with tumor cells. After the tumor volume grew to 50-100nm, they were divided into groups and given drugs once every three days for a total of 7 times. After the experiment, the tumors were removed and weighed.
[0049] Chinese patents CN102641243, CN102552142, and CN101874780 were selected as comparative documents, and docetaxel liposome lyophilized powder was prepared according to the prescriptions and processes of these patents. Specifically, the operation method and the dosage of components were the same as those in Example 1 of each document, and the amount of the original drug added in each example remained unchanged, only the original drug was replaced by docetaxel, and then docetaxel liposome lyophilized powder was prepared to observe the quality differences of the preparations and the in vivo and in vitro efficacy.
[0050] Table 1 Comparison of preparation indicators
[0051]
[0052] Table 2 Comparison of in vivo and in vitro efficacy
[0053]
[0054] The above data show that the addition of mannose to the liposomes reduces the cell proliferation inhibition rate and the average tumor weight, thereby playing a tumor inhibition role, thereby solving the defects of existing liposomes, and the particle size of the obtained preparation is below 120nm, which helps the liposomes to target and enrich the tumor site; and the liposome polydispersity index is low (PDI<0.2), indicating that the prepared liposomes have uniform particle size distribution, good stability, and are more conducive to being taken up by tumor cells, thereby achieving better anti-tumor effects. The encapsulation rate is greater than 90%, with a light blue opalescence, which meets the requirements of the pharmacopoeia and can effectively exert the drug effect. The appearance and color of the freeze-dried sample are uniform, the pores are dense, and the looseness is full (see Figure 1 ), good stability. While ensuring the original efficacy of the drug, the inhibitory effect of mannose on tumors is increased, and the efficacy is better.
[0055] The above embodiments are merely examples for illustrating the content of the technical solutions of the present invention, but the implementation of the present invention is not limited to the above embodiments. Any other changes, modifications, substitutions, combinations, simplifications, degraded technical solutions or means that do not deviate from the spirit and principles of the present invention should be regarded as equivalent or replacement methods of the technical solutions of the present invention and should be included in the protection scope of the present invention.
Claims
1. A liposome composition of docetaxel, characterized in that: The composition comprises 1) docetaxel or its derivatives; 2) lipid membrane material; 3) other excipients for preparing liposome drugs; by mass percentage, 0.01%-10% docetaxel or its derivatives, 20%-50% lipid membrane material, and the remainder is other excipients for preparing liposome drugs; wherein the other excipients for preparing liposome drugs are antioxidants, lyophilization protective agents and carriers, the carrier contains mannose, and the amount of mannose added is 80-100% of the mass of the carrier; The other excipients used to prepare the liposome drug are calculated by weight percentage, 20%-50% lyophilization protectant and 15%-50% carrier, and the balance is antioxidant; The lipid membrane material is one or more of natural soybean lecithin, egg yolk lecithin, sphingomyelin, cholesterol, hydrogenated soybean lecithin, dioleoylphosphatidylcholine, dimyristoylphosphatidylcholine, 1-palmitoyl-2-oleoyl lecithin, distearoylphosphatidylglycerol, dipalmitoylphosphatidylglycerol, dimyristoylphosphatidylglycerol, and phosphatidylethanolamine; The antioxidant component is one or more of α-tocopherol, vitamin E, threonine, lysine, and vitamin C; The freeze-drying protective agent is one or more of glucose, mannitol, trehalose, lactose, sucrose, and dextran; The carrier is mannose or a mixture containing mannose.
2. The liposome composition of docetaxel according to claim 1, characterized in that: The mixture containing mannose is a mixture of mannose and one or more of the following substances, and the following substances are selected from sodium chloride, glucose, lactose, sucrose, and trehalose.
3. The liposome composition of docetaxel according to claim 1, characterized in that: The mannose is chitosan formed by sugar metabolism of mannose, aminomannose, chitosan and octadecylamine.
4. A method for preparing the docetaxel liposome composition according to claim 1, characterized in that: (1) Film formation: docetaxel or its derivative, lipid film material and antioxidant are mixed with an organic solvent according to the above proportions, a carrier is added after mixing, and the mixture is further mixed. After mixing, the organic solvent is removed by heating at 20°C to 80°C under reduced pressure to obtain a dry film; (2) Hydration: Add a hydration medium containing a lyophilization protective agent to the obtained dry film, and stir in a constant temperature water bath at 20°C to 80°C to obtain a liposome suspension; (3) Granulation: The liposome suspension is granulated by microfluidization, high-pressure homogenization, ultrasound or extrusion to obtain a liposome intermediate; the intermediate is filtered, sterilized and freeze-dried to obtain liposomes.
5. The preparation method according to claim 4, characterized in that: The antioxidant, lyophilization protectant and carrier are all added in the above proportions; wherein the lyophilization protectant is added in step (2).
6. The preparation method according to claim 4, characterized in that: The organic solvent is one or more of anhydrous ethanol, dichloromethane and chloroform.
7. The preparation method according to claim 4, characterized in that: The hydration medium is one or more of purified water, physiological saline, pH 3-8 buffered salt solution, threonine solution, and glycine solution.
Citation Information
Patent Citations
Mannose-modified solid lipid nanoparticle plural gel and preparation method thereof
CN102670484A
Injection docetaxel nanoparticle and preparation method thereof
CN103462906A
Mannose derivative cation liposome nanoparticle preparation method
CN105585598A
Docetaxel liposome and preparation method thereof
CN111939130A
Preparation of docetaxel long-circulating liposome and freeze-dried powder injection thereof
CN101322689A
